Navigation Links
Pepscan Therapeutics Announces Establishment of Scientific Advisory Board
Date:9/28/2010

Pepscan Therapeutics Announces Establishment of Scientific Advisory Board -- LELYSTAD, The Netherlands, September 28, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Pepscan Therapeutics Announces Establishment of Scientific Advisory Board

 

LELYSTAD, The Netherlands, September 28, 2010 /PRNewswire/ -- Pepscan Therapeutics, the Netherlands-based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced the establishment of a Scientific Advisory Board (SAB). The SAB will guide the company in the further development and application of its core protein mimicking technology for the creation of novel therapeutic peptide drugs and monoclonal antibodies.

The Scientific Advisory Board is chaired by Sir Gregory Winter, a scientific pioneer of protein engineering and therapeutic monoclonal antibodies. He invented techniques to make humanized and fully human antibodies for therapeutic uses. Winter co-founded Cambridge Antibody Technologies, Domantis and Bicycle Therapeutics and is Deputy Director at the Laboratory of Molecular Biology, as well as at the MRC Centre for Protein Engineering, in Cambridge (UK).

Other distinguished members of the Scientific Advisory Board are:

Andrew Hamilton, the Vice-Chancellor of the University of Oxford and former Professor of Chemistry at Yale, a leading expert in the field of mimics of protein surface domains;

Andreas Pluckthun, Professor of Biochemistry at the University of Zurich and co-director of the department, a renowned pioneer in the antibody, protein engineering and directed evolution field, and co-founder of Morphosys and Molecular Partners;

Reinhold Foerster, Professor of immunology at the Medical School in Hannover, and an internationally acknowledged expert on chemokine receptors.

"We are very pleased with the formation of our Scientific Advisory Board and feel honored to collaborate with this experienced team that is highly committed advising the Company on moving forward its research and development program," said Wim Mol, CEO of Pepscan. "The complementary knowledge of the renowned scientists in this team will play a significant role in our R&D programs and success of the company."

Peter Timmerman, Chief Technology Officer of Pepscan and Professor in Protein Mimetic Chemistry at the University of Amsterdam, commented: " With this team of experts we get access to virtually all key aspects of antibody and GPCR-technology that are crucial for high-profile product discovery and development in that area. Yet it is also important to note that with this team we do not only cover expertise in antibody development, but also in the area of therapeutic peptides, a field that is rapidly growing and gaining increased interest from large pharma companies."

About Pepscan Therapeutics

Pepscan Therapeutics is a privately held company based in Lelystad, The Netherlands. Pepscan is using its proprietary high throughput CLIPS protein mimicking technology for the development of novel constrained therapeutic peptides and monoclonal antibodies against intractable targets like GPCR's. Besides its pipeline of proprietary anti-GPCR monoclonal antibody products Pepscan has various ongoing collaborations with leading pharmaceutical and biotech companies to develop novel therapeutics based on its proprietary CLIPS technology.

About CLIPS technology

CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains and hitherto have been used in antibody and vaccine programs to create superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).


'/>"/>
SOURCE Pepscan Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pepscan Achieves First Milestone in Research Collaboration With Genmab
2. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
3. Dutch Biotech Company Pepscan Appoints New CEO
4. Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... two-dimensional representations of a complex biological network, a depiction of a system of ... mess,” said Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):